New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation

Maria I. Aguilar; Ruth S. Kuo; William D. Freeman

doi:10.1016/j.ncl.2013.03.001

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation

Maria I. Aguilar, Ruth S. Kuo, William D. Freeman

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.

Original language	English (US)
Pages (from-to)	659-675
Number of pages	17
Journal	Neurologic clinics
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.ncl.2013.03.001
State	Published - Aug 2013

Keywords

Anticoagulation
Apixaban
Atrial fibrillation
Dabigatran
Direct thrombin inhibitors
Edoxaban
Factor Xa inhibitors
Reversal
Rivaroxaban
Stroke

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/j.ncl.2013.03.001

Cite this

@article{b583061a71664c2189d67c6fc099b19d,

title = "New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation",

abstract = "New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.",

keywords = "Anticoagulation, Apixaban, Atrial fibrillation, Dabigatran, Direct thrombin inhibitors, Edoxaban, Factor Xa inhibitors, Reversal, Rivaroxaban, Stroke",

author = "Aguilar, {Maria I.} and Kuo, {Ruth S.} and Freeman, {William D.}",

year = "2013",

month = aug,

doi = "10.1016/j.ncl.2013.03.001",

language = "English (US)",

volume = "31",

pages = "659--675",

journal = "Neurologic clinics",

issn = "0733-8619",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation

AU - Aguilar, Maria I.

AU - Kuo, Ruth S.

AU - Freeman, William D.

PY - 2013/8

Y1 - 2013/8

N2 - New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.

AB - New oral anticoagulants have been found to be as efficacious as warfarin and safer in terms of intracranial bleeding. All patients with nonvalvular atrial fibrillation should receive antithrombotic therapy for stroke prevention. For those at low risk, antiplatelet therapy is probably sufficient. For those at intermediate or high risk, anticoagulation is superior to antiplatelet therapy. Four oral anticoagulants are currently approved for stroke and systemic embolism prevention in atrial fibrillation: warfarin, dabigatran, rivaroxaban, and apixaban. Management of bleeding complications while on the new agents remains an area of concern and management is based on anecdotal experience and observational studies.

KW - Anticoagulation

KW - Apixaban

KW - Atrial fibrillation

KW - Dabigatran

KW - Direct thrombin inhibitors

KW - Edoxaban

KW - Factor Xa inhibitors

KW - Reversal

KW - Rivaroxaban

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84881018595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881018595&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2013.03.001

DO - 10.1016/j.ncl.2013.03.001

M3 - Review article

C2 - 23896498

AN - SCOPUS:84881018595

SN - 0733-8619

VL - 31

SP - 659

EP - 675

JO - Neurologic clinics

JF - Neurologic clinics

IS - 3

ER -

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this